SCYNEXIS (SCYX) Insider Guy Macdonald Buys 2,875 Shares

Multiple Insiders Buy SCYNEXIS Shares

On June 26, 2026, Guy Macdonald and four other insiders at SCYNEXIS, Inc. (NasdaqCM: SCYX) each acquired 2,875 shares of the company's common stock. These transactions were disclosed in reports filed with the Securities and Exchange Commission. The move represents a coordinated show of support from the company's leadership team, as all five insiders purchased the exact same number of shares on the same date.

Insider Buying and Selling at SCYNEXIS, Inc.

The buying activity on June 26, 2026, extended well beyond Guy Macdonald. David Hastings, Tinmouth Brian Philippe, Ann Hanham, and Armando Anido also each picked up 2,875 shares. None of these transactions were reported as being part of a Rule 10b5-1 trading plan, which is a pre-arranged schedule insiders sometimes use to buy or sell shares at set times. This cluster of buying follows several similar moves by these same individuals earlier in the year, as they continue to build their personal stakes in the biotechnology firm.

SCYX Stock Performance Context

On Wednesday, shares of SCYNEXIS were trading around $4.07. This price level puts the stock in the lower half of its performance over the last year. The shares have traded as high as $9.12 and as low as $3.53 over the past 52 weeks. The stock is currently trading below its 50-day moving average of $4.77 and its 200-day moving average of $5.66, which are common benchmarks used to track price trends. With a market value of about $43.8 million, the company is considered a small-cap player in the drug manufacturing industry.

Recent Financial Results

In its most recent financial reports, SCYNEXIS posted revenue of $19.22 million. However, the company saw a revenue decline of 82.8% compared to the prior period. The firm is not currently profitable, reporting a net loss and a negative return on equity of 18.4%. Despite the losses, the company has a very high current ratio of 9.65, which suggests it has plenty of cash and short-term assets to meet its immediate financial obligations.

Analysts Set New Price Targets

Wall Street analysts generally see much higher value in the stock than where it currently trades. On August 13, 2026, Guggenheim kept its Buy rating on the stock and set a price target of $33.00. Across the three analysts who cover the company, the average price target is $36.55, with the most optimistic target sitting at $44.64. These targets suggest that analysts believe the company's drug pipeline could lead to a major recovery in the share price.

About SCYNEXIS, Inc.

SCYNEXIS is a biotech company based in Jersey City, New Jersey, that focuses on creating medicines to fight dangerous fungal infections. Their main product is Brexafemme, which is used to treat and prevent yeast infections. They are also working on a new treatment called SCY-247, which is currently in early-stage clinical trials. The company's work is vital for patients who have infections that don't respond well to traditional antifungal drugs.

What to Watch at SCYX

Investors will likely look to the next earnings report, scheduled for November 4, 2026, for updates on the company's clinical trials and sales growth. While the recent insider buying shows confidence from the leadership team, these filings only show past transactions and may not reflect what the insiders are doing with their shares today. The company's ability to reach profitability remains the primary long-term story for shareholders to follow.